Related Experiment Video
Updated: May 27, 2026

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial
Andrew Grey1, Mark Bolland, Sumwai Wong
1Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand. a.grey@auckland.ac.nz
Single doses of zoledronate below 5 mg demonstrated significant bone mineral density increases and reduced bone turnover in postmenopausal women. Further trials are warranted to assess the fracture efficacy of these lower zoledronate doses.
Area of Science:
- Bone biology and osteoporosis research
- Pharmacology and drug development
Background:
- Annual intravenous administration of 5 mg zoledronate is established for decreasing fracture risk.
- The skeletal effects of zoledronate doses below 4 mg have not been previously evaluated.
Purpose of the Study:
- To investigate the skeletal effects of single intravenous doses of zoledronate at 5 mg or less.
- To assess changes in bone mineral density and bone turnover markers.
Main Methods:
- A 1-year, double-blind, randomized, placebo-controlled trial involving 180 postmenopausal women with osteopenia.
- Single intravenous administration of zoledronate (1 mg, 2.5 mg, or 5 mg) or placebo.
- Primary endpoint: change in lumbar spine bone mineral density (BMD); Secondary endpoints: changes in hip and total body BMD, and bone turnover markers.
Main Results:
- All zoledronate dose groups showed statistically significant increases in lumbar spine and total hip BMD compared to placebo after 12 months.
- Bone turnover markers (β-CTX and P1NP) were significantly reduced by at least 40% in all zoledronate groups compared to placebo.
- A dose-dependent effect of zoledronate was observed on bone turnover markers.
Conclusions:
- Single intravenous doses of zoledronate below 5 mg exhibit significant antiresorptive effects.
- These findings support the justification for clinical trials to evaluate the antifracture efficacy of lower zoledronate doses.
Related Concept Videos
Osteoclasts in Bone Remodeling
Bone Remodeling
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
Drug Dosing: Obese Patients